TIDMOBI
Ondine Biomedical Inc.
31 October 2023
31 October 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or the "Company")
Steriwave use expanded following successful pilot
-- Alberta Health Services has expanded its use of Steriwave
nasal photodisinfection to reduce the incidence of surgical site
infections (SSIs) in orthopedic surgery following a successful
pilot at the Mazankowski Alberta Heart Institute.
-- SSIs, the most common of healthcare-associated infections
(HAIs), are a significant burden to healthcare systems as well as
to patients, with the estimated cost of a prosthetic hip or knee
infection ranging from C$31,000 to more than C$100,000. [1]
Ondine Biomedical Inc (AIM: OBI), the Canadian life sciences
company developing non-antibiotic photodisinfection therapies to
prevent and treat healthcare-associated and drug-resistant
infections announces that Alberta Health Services has confirmed
that it is expanding its use of Ondine's Steriwave (R) nasal
photodisinfection following early data from its pilot introduction
at the Mazankowski Alberta Heart Institute, which saw significant
reductions in surgical site infections following cardiac surgery.
The Royal Alexandra Hospital in Edmonton, Canada, will use
Steriwave nasal photodisinfection prior to its c. 3,000 orthopedic
surgeries over the next year.
Ondine has pioneered nasal photodisinfection as a rapid,
non-antibiotic method for decolonizing the nose of the pathogens
carried by patients that can lead to HAIs. Steriwave uses a
proprietary red light-activated agent to eliminate
infection-causing bacteria, viruses, and fungi in the nose, a major
reservoir of germs [2] , without causing resistance. At the
Mazankowski Alberta Heart Institute, Steriwave replaced the
previous standard of care, the antibiotic mupirocin. Mupirocin is
commonly used for nasal decolonization to prevent SSIs, but has
poor rates of patient compliance and reported resistance rates as
high as 81%. [3]
Ondine Biomedical's CEO Carolyn Cross said:
"We are very pleased to be collaborating with Alberta Health
Services to reduce the incidence of SSIs in Alberta without
generating antibiotic resistance. The successful initial
implementation of Steriwave into the pre-surgical treatment
protocols at the Mazankowski Alberta Heart Institute has driven
rapid adoption of Steriwave for orthopedic surgeries at the Royal
Alexandra Hospital.
"The rising rate of antimicrobial resistance (AMR) makes it more
important than ever to have cost-effective, non-antibiotic methods
for preventing HAIs. Alongside growing global concerns about the
consequences of AMR, we are seeing more hospitals looking to move
away from topical antibiotic nasal decolonization. In addition to
growing resistance, topical antibiotics require patient compliance
with twice daily treatments for five days to achieve efficacy on a
limited number of bacterial species as compared to five minutes for
photodisinfection to eradicate a broad spectrum of bacteria,
viruses and fungi just prior to surgery. Photodisinfection's rapid
eradication of potentially harmful pathogens gives healthcare
professionals better control over patient outcomes."
Rising rates of AMR are making infections more difficult to
prevent and treat, as some commonly used antibiotics are now
ineffective. [4] Many hospitals are adapting their infection
prevention protocols to combat drug-resistant pathogens. As many as
one in 19 deaths in Canada is now attributable to
antibiotic-resistant infections, [5] and t he cost of AMR to the
Canadian healthcare sector is also projected to increase to $7.6
billion per year by 2050. ([6]) SSIs, the most common of HAIs, are
a big burden to healthcare systems as well as to patients, with the
estimated cost of a prosthetic hip or knee infection ranging from
C$31,000 to more than C$100,000. [7]
Steriwave is already in use in major hospitals across Canada,
including Vancouver General and UBC Hospitals in BC, The Ottawa
Hospital (Ontario), Montreal Heart Institute, Sherbrooke Fleurimont
(Quebec), and the Queen Elizabeth II Health Sciences Centre (Nova
Scotia). In hospital settings, pre-surgical use of Steriwave has
resulted in significant improvement in post-surgical outcomes
including lower rates of infection, reduced patient length of stay,
fewer readmissions, lower rates of antibiotic prescribing and
significant cost savings. [8](, [9] , [10])
**S**
Ondine Biomedical Inc.
+001 (604) 665
Carolyn Cross, CEO 0555
Singer Capital Markets (Nominated Adviser
and Joint Broker)
+44 (0)20 7496
Aubrey Powell, Asha Chotai, Sam Butcher 3000
RBC Capital Markets (Joint Broker)
+44 (0)20 7653
Rupert Walford, Kathryn Deegan 4000
Vane Percy & Roberts (Media Contact)
+44 (0)77 1000
Simon Vane Percy, Amanda Bernard 5910
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company
innovating in the field of photodisinfection therapies. Ondine has
a pipeline of investigational products, based on its proprietary
photodisinfection platform, in various stages of development.
Products beyond nasal photodisinfection include therapies for a
variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.
About Nasal Photodisinfection
Ondine's nasal photodisinfection is a patented technology using
a proprietary photosensitizer (non- antibiotic, light-activated
agent) to destroy pathogens. The photodisinfection treatment is
carried out by a trained healthcare professional and is an easy to
use, painless, two-step process. The photosensitizer is applied to
each nostril using a nasal swab, followed by illumination of the
area with a specific wavelength of red laser light for less than
five minutes. The light activates the photosensitizer, causing an
oxidative burst that is lethal to all types of pathogens. A key
benefit of this approach, unlike with antibiotics, is that
pathogens do not develop resistance to the therapy.
Nasal decolonization with antibiotics is already standard
practice in many hospitals prior to surgery, as pathogens in a
patient's nasal cavities are a major cause of surgical site
infections (SSIs). Nasal decolonization is recommended in the 2016
WHO Global guidelines for the prevention of surgical site
infections, [11] and the Society for Healthcare Epidemiology of
America (SHEA) guidelines, published in May 2023, recommend nasal
decolonization for major surgical procedures. [12] H owever, there
is a growing need to reduce antibiotic use and find non-antibiotic
methods of nasal decolonization as resistance rates have been
reported as high as 81%. [13]
Ondine's nasal photodisinfection system has a CE mark in Europe
and the UK and is approved in Canada and several other countries
under the name Steriwave(R). It has been used in Canada for over
ten years, with no serious adverse events reported. In the US, it
is currently undergoing clinical trials for regulatory
approval.
About Alberta Health Services
Alberta Health Services (AHS) is proud to be part of Canada's
first and largest provincewide, integrated health system,
responsible for delivering health services to more than 4.4 million
people living in Alberta, as well as to some residents of
Saskatchewan, B.C. and the Northwest Territories.
AHS has 106 acute care hospitals, five stand-alone psychiatric
facilities, 8,523 acute care beds, 28,360 continuing care
beds/spaces and 3,077 addiction and mental health beds/spaces, plus
equity partnership in 40 primary care networks. Programs and
services are offered at more than 900 facilities throughout the
province, including hospitals, clinics, continuing care facilities,
cancer centres, mental health facilities and community health
sites.
[1] Rennert-May ED, Conly J, Smith S, et al. The cost of
managing complex surgical site infections following primary hip and
knee arthroplasty: A population-based cohort study in Alberta,
Canada. Infection Control & Hospital Epidemiology.
2018;39(10):1183-1188. doi:10.1017/ice.2018.199
[2] Liu Z, Norman G, Iheozor-Ejiofor Z, Wong JK, Crosbie EJ,
Wilson P. Nasal decontamination for the prevention of surgical site
infection in Staphylococcus aureus carriers. Cochrane Database Syst
Rev. 2017 May 18;5(5):CD012462. doi:
10.1002/14651858.CD012462.pub2. PMID: 28516472; PMCID:
PMC6481881.
[3] Poovelikunnel T, Gethin G, Humphreys H. Mupirocin
resistance: clinical implications and potential alternatives for
the eradication of MRSA. J Antimicrob Chemother.
2015;70(10):2681-2692. doi:10.1093/jac/dkv169
[4] Poovelikunnel T, Gethin G, Humphreys H. Mupirocin
resistance: clinical implications and potential alternatives for
the eradication of MRSA. J Antimicrob Chemother. 2015
Oct;70(10):2681-92. doi: 10.1093/jac/dkv169. Epub 2015 Jul 3.
[5] Healthcare-associated infections and antimicrobial
resistance in Canadian acute care hospitals, CCDR 49(5) -
Canada.ca
[6] Healthcare-associated infections and antimicrobial
resistance in Canadian acute care hospitals, CCDR 49(5) -
Canada.ca
[7] Rennert-May ED, Conly J, Smith S, et al. The cost of
managing complex surgical site infections following primary hip and
knee arthroplasty: A population-based cohort study in Alberta,
Canada. Infection Control & Hospital Epidemiology.
2018;39(10):1183-1188. doi:10.1017/ice.2018.199
[8] Banaszek D, Inglis T, Tamir Ailon T, Charest-Morin R, Dea N,
Fisher C, Kwon B, Paquette S, Street J. The efficacy and
cost-effectiveness of photodynamic therapy in prevention of
surgical site infection. The Spine Journal, Volume 19, Issue 9,
Supplement, 2019, Page S138.
[9]
https://www.londonstockexchange.com/news-article/OBI/ottawa-hospital-presents-steriwave-study-
results/15860312
[10] Bryce E, Wong T, Forrester L, et al. Nasal
photodisinfection and chlorhexidine wipes decrease surgical site
infections: a historical control study and propensity analysis
[published correction appears in J Hosp Infect. 2015 Sep;91(1):93].
J Hosp Infect. 2014;88(2):89-95. doi:10.1016/j.jhin.2014.06.017
[11]
https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2
[12] Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies
to prevent surgical site infections in acute-care hospitals: 2022
Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720.
doi:10.1017/ice.2023.67
[13] Poovelikunnel T, Gethin G, Humphreys H. Mupirocin
resistance: clinical implications and potential alternatives for
the eradication of MRSA. J Antimicrob Chemother.
2015;70(10):2681-2692. doi:10.1093/jac/dkv169
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGIBDGUUXDGXB
(END) Dow Jones Newswires
October 31, 2023 05:00 ET (09:00 GMT)
Ondine Biomedical (LSE:OBI)
過去 株価チャート
から 4 2024 まで 5 2024
Ondine Biomedical (LSE:OBI)
過去 株価チャート
から 5 2023 まで 5 2024